Articles tagged with Breast Neoplasms
Researchers at UCSF have discovered a new therapeutic target, SRC, present on up to half of all tumors, which can be targeted with antibody drugs. The enzyme, normally hidden inside cells, is exposed on the surface of tumor cells due to an overactive disposal system, making it an easy target for cancer-killing antibodies.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
Biologists at Cold Spring Harbor Laboratory have made a significant discovery that could lead to better patient outcomes for ER+ breast cancer patients. Inhibiting the BPTF protein in mice can slow cancer metastasis and restore tumors' susceptibility to hormone therapy, offering new hope for treating resistant forms of the disease.
The NCCN Guidelines Navigator now covers treatment for over a dozen cancer types, including hereditary risk assessment, providing seamless navigation and search capabilities. The new format aims to improve treatment decision-making based on the latest evidence and expert-consensus.
Researchers at Cold Spring Harbor Laboratory have created a tool called MaGNet to analyze the branching structure of mouse mammary glands. The system enables precise comparison of stained images and quantifies data with ease, allowing for earlier detection of breast cancer and investigation into hormonal changes and treatments.
This study investigates the diagnostic performance of ATR-FTIR spectroscopy in discriminating normal breast tissue from breast tumors. The analysis reveals that specific biomarkers, particularly the cytoplasm-nucleus ratio marker, demonstrate remarkable diagnostic accuracy.
A new breast scan system combines photoacoustic and ultrasound imaging to produce clear 3D images of common breast cancer subtypes. The system, called OneTouch-PAT, takes less than a minute to complete and excels at detecting suspicious lesions in women with dense breast tissue.
The ESMO Breast Cancer 2025 congress will cover topics such as circulating tumour DNA, immunotherapies, and emerging therapies for managing breast cancer. The event will feature key findings on predictive biomarkers, ctDNA, and tumour-infiltrating lymphocytes.
Researchers developed a nanobody that targets V-ATPase c subunit and inhibits tumor cell invasion and metastasis. The nanobody was tested on 4T1-12B mouse breast cancer cells implanted in mice, where it showed effectiveness in preventing lung metastasis.
Researchers discuss HER2 in breast cancer, highlighting the prognostic and predictive factors. They found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer, challenging the long-held view that HER2-negative tumors do not benefit from trastuzumab-based therapy.
A study published in the Canadian Association of Radiologists Journal shows an increase in breast cancer diagnoses among females in their Twenties, Thirties, and Forties. Younger women are more likely to be diagnosed at later stages and with more aggressive cancer.
Researchers revisited melatonin's effects on cancer in mice, finding that nighttime administration inhibits chemically induced mammary tumor development. The study highlights the importance of timing in using this freely available compound for cancer prevention and treatment.
Researchers discovered that Osteopontin induces mitochondrial biogenesis in deadherent breast tumor cells, which aids metastatic success. The study suggests a possible mechanism and targets for treating cancer metastasis by increasing ATP levels and mitochondrial mass.
A study of 185 women found that high neighborhood deprivation was associated with changes in DNA methylation and gene expression in Black women with breast cancer. This suggests a potential link between environmental factors and biological susceptibility to chronic diseases.
Researchers analyzed BORIS mutations and protein expression in breast cancer tissue samples, finding frequent mutations associated with breast carcinoma progression. The study suggests the BORIS gene as a potential biomarker for breast cancer.
The American College of Radiology (ACR) has introduced new guidelines recommending earlier and more intensive breast cancer screening for high-risk women, including Black women. According to the ACR, risk assessment by age 25 is necessary to determine if screening should start before age 40.
Breast tumor microbes vary significantly among women of different ethnicities, with potential implications for personalized care and disease progression. Researchers identified distinct microbial biomarkers associated with genes involved in tumor aggressiveness and immune response.
A 30-year follow-up study of patients with early breast cancer found that radiotherapy does not improve overall survival rates after 10 years but reduces the risk of recurrence in the same breast. The study's findings challenge traditional concepts of long-term anti-cancer benefits of radiotherapy.
Filopodia contribute to building a barrier surrounding breast tumours, blocking their escape. Cancer cells lacking Myosin-10 cannot maintain this barrier, making it easier for them to spread.
Research from UVA Cancer Center finds that an unhealthy gut microbiome can trigger changes in normal breast tissue, facilitating cancer's spread to other parts of the body. The study suggests that targeting the gut-mast cell relationship could help prevent breast cancer recurrence and metastasis.
The analysis found that inadequate margin widths may result in higher risks of distant recurrence and breast cancer mortality, as well as increased local recurrence. The researchers recommend a minimum tumour free distance of 1mm from the margin for optimal oncological outcomes.
Researchers analyzed germline variants in breast cancer patients to identify their role in metastasis development. The study found that host genetic makeup contributes to metastasis through dysregulation of gene expression, promoting the dispersion of metastatic seeds and establishing a conducive environment for their growth.
A prospective study compared CEM and MRI for NAT response assessment in patients with breast cancer. CEM yielded comparable assessments of lesion size and RECIST categories as MRI, but with lower sensitivity for pathologic complete response. Delayed CEM acquisition detected residual ductal carcinoma in situ (DCIS).
A study found that 12% of recurrent ductal carcinoma in situ (DCIS) cases were new primary lesions unrelated to the original tumor. These findings suggest that genetic biomarkers for predicting recurrence may not be effective for all patients.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
Researchers developed a new deep learning algorithm that allows for real-time reconstruction of images combining optical and magnetic resonance imaging data. The algorithm, Z-Net, enables faster image generation and can be trained with simulated data, improving breast cancer detection.
Researchers found that high levels of MYO10 induce chronic inflammation, reducing T cell function, but also increasing immune response. This led to improved outcomes with immune checkpoint blockade therapy for certain tumors.
Researchers employed iTRAQ based quantitative proteomics to characterize protein alterations in fibroepithelial lesions (FELs) of the breast. The study identified three candidate biomarkers: MUCL1, HTRA1, and VEGFD, which were uniquely expressed in FAD, borderline, and malignant PTs, respectively.
The BreastPathQ Grand Challenge produced encouraging results, indicating a path toward integrating artificial intelligence to streamline clinical assessment of breast cancer. Thirty-nine teams from 12 countries developed automated methods for analyzing microscopy images of breast tissue and assessing pathology.
Researchers used quantitative proteomics to stratify fibroepithelial breast lesions, identifying three candidate biomarkers: MUCL1, HTRA1, and VEGFD. These markers show promise in augmenting existing diagnosis and monitoring disease progression.
Research found that vitamin D3 reduces both HAS2 gene expression and hyaluronic acid synthesis in multiple models of breast cancer. The study suggests a novel role for vitamin D3 and the VDR in control of HA synthesis, which likely contributes to its anti-cancer actions.
Researchers at Lund University developed a computational model to detect and identify genetic mutations in breast tumours using RNA sequencing. The study found that almost 87% of patients had at least one mutation for which potential drugs exist, with specific genes like PIK3CA associated with good prognosis.
Researchers at MIT developed a vaccine that dramatically enhances antitumor T cell population and allows cells to invade solid tumors. The booster vaccination increased the success rate of CAR-T cell therapy from 10% to 60% in mice, eliminating tumors in 60% of animals.
Researchers develop a bio-scoring system to improve prognostication for dogs with mammary tumors, identifying those at higher risk of metastasis. The system uses tumor stage, grade, and histological type to provide a clearer picture of treatment options.
The study found that accelerated partial breast irradiation (PBI) was not statistically superior to whole breast irradiation (WBI) in preventing ipsilateral breast tumor recurrence. However, PBI showed promise as a less burdensome treatment option for some women, with smaller differences in relapse-free interval and grade 3 toxicity.
Researchers develop new theory to explain how tumors spread, revealing competition between forces that shape their growth. The 'active wetting' model suggests tumors behave like active drops, with cells creating forces and moving on their own.
A new study published in Radiology found that pre-operative supine MRI can provide more detailed and accurate information than prone MRI, helping surgeons detect remnant tumors and ensure clear margins. This could lead to effective tumor removal and reduce the need for re-operations.
Research from University of Eastern Finland and Kuopio University Hospital found that very low mammographic breast density is associated with worse prognosis in breast cancer patients. Low density combined with high hyaluronan levels in tumors predicted poorer survival rates.
A new trial found that full-dose radiotherapy to the whole breast is not necessary for women with low-risk early breast cancer. The study showed very low rates of local recurrence and minimal side effects across all treatment groups, suggesting that partial breast radiotherapy may be sufficient for many patients.
A team of Singaporean scientists has identified the genetic landscape of fibroepithelial breast tumors, revealing how they progress from benign to cancerous types. The study's findings may improve diagnostic accuracy and enhance clinical intervention for patients with these tumors.
A new screening method, tomosynthesis, has been found to detect 40% more breast cancers than traditional mammography. The technique uses 3D X-ray images and reduces discomfort and pain during the examination.
The study, which analyzed data from the National Cancer Data Base, found that 59% of women who received pre-surgery chemotherapy had breast conservation therapy. Women with larger tumors were also more likely to opt for pre-surgery chemotherapy and lumpectomy versus mastectomy.
A team of researchers from the University of Alberta has shown that betaretrovirus infects patients with primary biliary cirrhosis, a rare autoimmune liver disease. The study used next-generation sequencing to identify viral DNA integration sites in patient genomes, providing evidence of viral infection.
Researchers inhibit autotaxin, an enzyme that promotes cancer cell survival and metastasis, decreasing tumor growth by up to 70% and improving chemotherapy effectiveness. The discovery offers a new therapy potential for breast and thyroid cancer patients.
A multi-disciplinary team of scientists has discovered that a gene called MED12 is altered in nearly 60% of fibroadenomas, the most common benign breast tumours diagnosed in women. The study's findings have potential applications in distinguishing fibroadenomas from breast cancer and developing targeted therapies.
A new imaging technique combining four approaches can distinguish between malignant and benign breast tumors with high accuracy, potentially avoiding unnecessary biopsies. The multiparameter PET-MRI method showed a 96% success rate in distinguishing malignant from benign tumors.
Researchers identified epigenetic alterations associated with the aging process in disease-free breast tissues, which are further altered in breast tumors. These changes may contribute to the development of breast cancer by increasing cancer risk.
Researchers at Lund University found that lymph nodes provide a more accurate picture of breast cancer prognosis than breast tissue alone. Analyzing the proliferation, hormone receptor status, and HER2 status of lymph nodes showed significantly improved results in predicting metastases and disease recurrence.
Researchers developed a new technique using phase contrast tomography and EST algorithm to create high-quality 3D images of breast tissue, allowing for earlier and more accurate detection of breast tumors. The technique uses lower radiation doses than current CT scanners, enabling clearer images with sharper details.
A study published in the Journal of the National Cancer Institute found that a plant-based compound called phenethyl isothiocyanate (PEITC) slowed breast cancer growth in mice. PEITC was shown to reduce mammary carcinoma lesions by 56.3% and suppress tumor progression.
Researchers have developed a simple and cost-effective imaging device for breast tumor detection using a flexible wearable antenna system. The system shows promise of detecting breast cancer earlier than other methods by analyzing microwave signals from skin contact, reducing signal loss compared to traditional designs.
Researchers have discovered a new growth-driving protein, MYC, that drives the growth of aggressive triple-negative breast tumors. Blocking a cooperating protein, CDK, causes these tumors to regress in mice, offering a potential new target for treatment.
Researchers at McGill University Health Centre have identified parathyroid hormone-related protein (PTHrP) as a key player in breast cancer progression and metastasis. The study found that blocking PTHrP production can reduce tumor growth by 80-90% and prevent its spread to other organs.
A study published in the Journal of the American College of Surgeons found that Hispanic women are more likely to develop phyllodes tumors, a rare and unpredictable breast malignancy. The study also revealed higher-grade tumors in Hispanic patients and larger tumor sizes compared to other racial groups.
A study found that women with dense breasts are at higher risk of certain breast cancers and their tumors are more likely to be aggressive. Breast density was also linked to specific tumor characteristics, including ductal carcinoma in situ (DCIS) and estrogen receptor-negative tumors.
A new imaging agent called 18F FPPRGD2 targets breast tumor development by detecting angiogenesis, a process that forms new blood vessels in tissues. This allows for better clinical decisions and earlier identification of patients who are ideal candidates for aggressive therapies.
Researchers have identified a potential therapeutic target for basal-like ER-negative breast cancer. High levels of the protein NOS2 are associated with poor survival in these patients. Selective NOS2 inhibitors may offer new treatment options for this aggressive subtype.
Researchers at the University of Gothenburg have identified 12 genes linked to aggressive breast cancer, which could lead to more reliable prognoses and better treatment strategies. The study found that these genes are associated with an increased risk of tumor progression, cell growth, motility, and development.
The TARGIT-A trial found that targeted intraoperative radiotherapy (TARGIT) is non-inferior to whole breast external beam radiotherapy in reducing local recurrences. Patients who underwent TARGIT had similar recurrence rates to those receiving conventional radiotherapy, with lower rates of radiotherapy toxicity.
A Dartmouth study found that adjuvant radiotherapy can prevent tumor recurrence in patients with borderline-malignant and malignant phyllodes tumors after breast-conserving surgery. The treatment was effective in controlling the growth of tumors in nearly 80% of cases.